Yi Luo
Impact in
- Aging top 1%
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Cancer-related molecular mechanisms research 13
- MicroRNA in disease regulation 7
- Oncology 26
- Lung Cancer Research Studies 7
- Co-authors
- Lijian Shao (6 shared papers)Aimin Meng (4 shared papers)Daohong Zhou (4 shared papers)Wei Feng (4 shared papers)Jianhui Chang (4 shared papers)Norman E. Sharpless (2 shared papers)Martin Hauer‐Jensen (2 shared papers)Yingying Wang (1 shared paper)
- Journals
- Frontiers in Immunology (5 papers)Cell Death and Disease (5 papers)Biochemical and Biophysical Research Communications (4 papers)Frontiers in Oncology (3 papers)Biomedicine & Pharmacotherapy (3 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Yi Luo
145 papers receiving 8.7k citations
Yi Luo's Hit Papers
Peers
Comparison fields: 5 of 139
- Aging 231
- Pulmonary and Respiratory Medicine 3.6k
- Oncology 2.5k
- Cancer Research 1.3k
- Physiology 1000
Countries citing papers authored by Yi Luo
This map shows the geographic impact of Yi Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Luo more than expected).
Fields of papers citing papers by Yi Luo
This network shows the impact of papers produced by Yi Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Luo. The network helps show where Yi Luo may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 155 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Hit paper breakdown → | 2011 | 3516 |
| 2 | Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice Hit paper breakdown → | 2015 | 1495 |
| 3 | Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Hit paper breakdown → | 2015 | 401 |
| 4 | 2018 | 209 | |
| 5 | 2014 | 134 | |
| 6 | 2013 | 104 | |
| 7 | 2017 | 100 | |
| 8 | 2014 | 92 | |
| 9 | 2016 | 87 | |
| 10 | 2011 | 75 | |
| 11 | 2009 | 74 | |
| 12 | 2017 | 73 | |
| 13 | 2011 | 69 | |
| 14 | 2022 | 67 | |
| 15 | 2018 | 66 | |
| 16 | 2013 | 62 | |
| 17 | 2013 | 62 | |
| 18 | 2021 | 61 | |
| 19 | 2012 | 60 | |
| 20 | 2017 | 59 |
About Yi Luo
Yi Luo is a scholar working on Cancer Research, Oncology, Hematology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 155 papers that have together received 8.9k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (13 papers), RNA modifications and cancer (10 papers), Lung Cancer Research Studies (7 papers), Immune Cell Function and Interaction (7 papers), MicroRNA in disease regulation (7 papers), Thyroid Cancer Diagnosis and Treatment (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Autophagy in Disease and Therapy (5 papers). The work is most often cited by research in Aging (231 citations), Pulmonary and Respiratory Medicine (3.6k citations), Oncology (2.5k citations), Cancer Research (1.3k citations) and Physiology (1000 citations). Yi Luo has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Lijian Shao, Aimin Meng, Daohong Zhou, Wei Feng, Jianhui Chang, Norman E. Sharpless, Martin Hauer‐Jensen, Yingying Wang, Xiaoyan Wang and Nukhet Aykin-Burns. Their work appears in journals such as Frontiers in Immunology, Cell Death and Disease, Biochemical and Biophysical Research Communications, Frontiers in Oncology and Biomedicine & Pharmacotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.